SCHEMBL6370676

SCHEMBL6370676

COc1ccc(Cl)cc1NC(=O)Nc1nnc(C(F)(F)F)s1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.61
TSHR P16473 1/20 0.56
HSD17B10 Q99714 1/20 0.56
RAF1 P04049 1/20 0.55
IGF1R P08069 1/20 0.55
FFAR2 O15552 1/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
KMT2A Q03164 7/20 0.51
MEN1 O00255 6/20 0.51
POLB P06746 2/20 0.51
TP53 P04637 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MAPT P10636 1/20 0.51
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6371395 0.85 RAF1 (0.56) CYP2C9TSHRHSD17B10RAF1IGF1R
SCHEMBL6371951 0.85 RAF1 (0.60) CYP2C9TSHRHSD17B10RAF1NPC1
SCHEMBL6371562 0.84 TSHR (0.77) CYP2C9TSHRHSD17B10RAF1NPC1
SCHEMBL6371142 0.84 POLB (0.61) IGF1RNPC1RAB9AKMT2AMEN1
SCHEMBL11873110 0.82 TAS1R3 (0.57) RAF1FFAR2NPC1RAB9AKMT2A
SCHEMBL6370925 0.82 NPC1 (0.54) CYP2C9TSHRHSD17B10RAF1IGF1R
SCHEMBL6377909 0.82 RAF1 (0.57) CYP2C9TSHRHSD17B10RAF1NPC1
SCHEMBL6370755 0.82 RAF1 (0.57) CYP2C9TSHRHSD17B10RAF1NPC1
SCHEMBL5245264 0.82 CYP2C9 (0.58) CYP2C9TSHRHSD17B10RAF1NPC1
SCHEMBL6372230 0.81 RAF1 (0.54) CYP2C9TSHRHSD17B10RAF1FFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2005-11-10 US claimed
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-16 US claimed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
WO-2003093250-A2 POSITIVE ALLOSTERIC MODULATORS OF THE NICOTINIC ACETYLCHOLINE RECEPTOR PHARMACIA & UPJOHN COMPANY (US) 2003-11-13 WO claimed
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2005-11-10 US disclosed
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-16 US disclosed
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PFIZER INC 2004-12-09 US disclosed
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254373-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 CYP2C9 2134/4885TSHR 369/4885HSD17B10 2567/4885
US-20030236287-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 CYP2C9 2134/4885TSHR 369/4885HSD17B10 2567/4885
US-20040249150-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA1, CHRNB1, CHRM1 CYP2C9 2134/4885TSHR 369/4885HSD17B10 2567/4885
US-20050250816-A1 Positive allosteric modulators of the nicotinic acetylcholine receptor CHRNA7, CHRNA1, CHRNA5 CYP2C9 1978/4885TSHR 344/4885HSD17B10 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.